News and Perspective

The FDA approved dupilumab as the first biologic for children aged 2-11 with chronic spontaneous urticaria (CSU) uncontrolled by antihistamines. Backed by the LIBERTY-CSU CUPID clinical program, the therapy significantly reduces itch and hive severity while maintaining a safety profile consistent with its known type 2 inflammation indications.